Jim Simons Bio Atla, Inc. Transaction History

Renaissance Technologies LLC

$63.6 Billion
Q1 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Bio Atla, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 996,300 shares of BCAB stock, worth $1.52 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

996,300

Previous 987,500 0.89%

Holding current value

$1.52 Million

Previous $2.43 Million 41.09%

% of portfolio

0.01%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$1.88 - $3.46 $16,544 - $30,448	8,800 Added 0.89%	996,300 $3.43 Million
Q4 2023 Feb 13, 2024	BUY	$1.27 - $3.18 $460,121 - $1.15 Million	362,300 Added 57.95%	987,500 $2.43 Million
Q3 2023 Nov 14, 2023	SELL	$1.7 - $3.07 $105,862 - $191,175	-62,272 Reduced 9.06%	625,200 $1.06 Million
Q2 2023 Aug 11, 2023	BUY	$2.83 - $3.87 $647,707 - $885,734	228,872 Added 49.91%	687,472 $2.06 Million
Q1 2023 May 12, 2023	SELL	$2.3 - $8.25 $47,839 - $171,600	-20,800 Reduced 4.34%	458,600 $1.23 Million

Q4 2022 Feb 13, 2023	SELL	$7.63 - $11.01 $657,706 - $949,062	-86,200 Reduced 15.24%	479,400 $3.96 Million
Q3 2022 Nov 14, 2022	SELL	$2.94 - $11.87 $631,512 - $2.55 Million	-214,800 Reduced 27.52%	565,600 $4.36 Million
Q2 2022 Aug 12, 2022	BUY	$2.13 - $5.38 $519,573 - $1.31 Million	243,931 Added 45.47%	780,400 $2.22 Million
Q1 2022 May 13, 2022	BUY	$4.38 - $18.78 $2.04 Million - $8.74 Million	465,569 Added 656.66%	536,469 $2.68 Million
Q4 2021 Feb 11, 2022	BUY	$19.0 - $30.95 $1.35 Million - $2.19 Million	70,900 New	70,900 $1.39 Million

Others Institutions Holding BCAB

# of Institutions

Shares Held

24.8M

Call Options Held

140K

Put Options Held

4.6K

View Full List

About BioAtla, Inc.

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $55.5M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

More about BCAB

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account